As a Free StocksGuide user, you can view scores for all 7,042 stocks worldwide.
12 Analysts have issued a Abeona Therapeutics, Inc. forecast:
12 Analysts have issued a Abeona Therapeutics, Inc. forecast:
| Sep '25 |
+/-
%
|
||
| Revenue | 0.40 0.40 |
-
|
|
| Gross Profit | -0.49 -0.49 |
-
|
|
| EBITDA | -82 -82 |
40%
40%
|
|
| EBIT (Operating Income) EBIT | -83 -83 |
37%
37%
|
|
| Net Profit | 82 82 |
216%
216%
|
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Abeona Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of gene therapy for severe and life threatening rare diseases. It programs include EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and ABO-101 (AAV NAGLU), an AAV based gene therapy for Sanfilippo syndrome type B (MPS IIIB). The company was founded in 1974 and is headquartered in New York, NY.
| Head office | United States |
| CEO | Vishwas Seshadri |
| Employees | 136 |
| Founded | 1974 |
| Website | abeonatherapeutics.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


